Noile-Immune Biotech (TSE:4893) Other Current Liabilities: 円34.67 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4893 Noile-Immune Biotech Inc TSE:4893
49 GF Score
Price 円141.00
GF Value 円4.30
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Other Current Liabilities?

Noile-Immune Biotech TSE:4893 49 Other Current Liabilities is 円34.67 Mil as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 49/100 and a GF Value™ of 円4.30 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Noile-Immune Biotech's other current liabilities for the quarter that ended in Dec. 2025 was 円34.67 Mil.

Noile-Immune Biotech's quarterly other current liabilities increased from Jun. 2025 (円33.02 Mil) to Sep. 2025 (円43.70 Mil) but then declined from Sep. 2025 (円43.70 Mil) to Dec. 2025 (円34.67 Mil).

Noile-Immune Biotech's annual other current liabilities increased from Dec. 2023 (円37.34 Mil) to Dec. 2024 (円37.34 Mil) but then declined from Dec. 2024 (円37.34 Mil) to Dec. 2025 (円34.67 Mil).

Noile-Immune Biotech Other Current Liabilities Related Terms

Noile-Immune Biotech Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Other Current Liabilities Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 27.93 99.06 37.34 37.34 34.67

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.60 33.02 43.70 34.67 36.04
TSE:4893
49GF Score
Noile-Immune Biotech Inc TSE:4893
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円34.67 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Other Current Liabilities of 円34.67 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Noile-Immune Biotech.
Is Noile-Immune Biotech's Other Current Liabilities too high?
Noile-Immune Biotech's current Other Current Liabilities is 円34.67 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Other Current Liabilities compare to VRTX and REGN?
Noile-Immune Biotech's Other Current Liabilities of 円34.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Noile-Immune Biotech. Noile-Immune Biotech's current Other Current Liabilities is 円34.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.30, compared to a current price of 円141.00 — trading 3179.1% above its estimated fair value. The current Other Current Liabilities is 円34.67 Mil. Noile-Immune Biotech's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Other Current Liabilities is 円34.67 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円141.00 is trading 3179.1% above its estimated GF Value™ of 円4.30. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Other Current Liabilities: 円34.67 Mil
  • GF Value™: 円4.30 vs. price of 円141.00 (3179.1% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
49GF Score

Get the complete analysis for TSE:4893

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円141.00
Price
円4.30
GF Value